Friday, 16 October 2026European Markets

BSA CRE Stock Plummets 30% As Session Ends, Investors React

Loading stream...

(vianews) - pierre vac bsa cre (cac 40: vacbt.pa) stock fell by 30.56% at 15:25 est on friday after five consecutive sessions of declines, creating a major setback in its performance, while cac 40 index experienced only minimal gain; adding only 0.29% to eur7,611.06 overall. even so, pierre vac bsa cre's final closing price still stood 0% below its 52-week high of eur0.36.

yearly analysis

based on available information, pierre vac bsa cre's stock is currently trading below its 52-week low of eur0.36 - this indicates poor performance over the past year and reaching its lowest point within that time frame. investors should remember that past performance is no guarantee of future outcomes and take other factors such as company financials, industry trends and overall market conditions into consideration before making their investment decisions.

more news about pierre vac bsa cre (vacbt.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com